Li Kang Biomedical Co., Ltd.
6242.TWO
Taipei Exchange36.10
TWD
+0.10
- -
Li Kang Biomedical Co., Ltd.
6242.TWO
(Taipei Exchange)
Recent
price
36.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Li Kang Biomedical Co., Ltd. primarily engages in the manufacturing and sale of supplement products, cosmeceuticals, and hygienic drink products. The company operates in traditional Chinese medicine-related segments, developing and promoting hygienic tea drinks with a specialization in Chinese herbal medicine ingredients. It also provides services in the management and consulting of tourism factory businesses and operates telemarketing services as part of its diversified business model. Li Kang Biomedical has cultivated a unique business model by integrating manufacturing and tourism service industries, notably through its "Tourism Factory" business divisions such as Li Kang Cultural Hall for Chinese Herbs Industry and Li Kang Tourism Factory of Health and Regime. The company further emphasizes channel operations through decentralized channels including tourism factories, telemarketing, and chain stores of traditional Chinese medicine pharmacies. Founded in 1982 and headquartered in Tainan City, Taiwan, Li Kang Biomedical was formerly known as BAFO Technologies Corporation and changed its name in 2014 to better reflect its core business focus. The company has expanded partnerships in recent years, including a significant collaboration with Intellego to distribute disinfection industry products in China and Asia under a USD 360 million deal spanning five years, illustrating its strategic expansion into health-related product sectors in the Asia region. Li Kang Biomedical targets markets primarily within Taiwan and broader Asia, applying its expertise in supplement, cosmeceutical, and herbal hygienic beverages toward consumers interested in health and wellness, as well as service-based tourism and telemarketing sectors. The company employs around 122 people and reported revenue of approximately TWD 565.52 million in 2024. Its ongoing business developments emphasize integrating health product manufacturing with tourism-based experiential marketing and expanding into new markets and product lines through partnerships and strategic sales channels, notably within traditional Chinese medicine and health-related consumer products. Overall, Li Kang Biomedical operates in consumer health, cosmetics, and tourism management sectors, combining product manufacturing with innovative service models to leverage the growing interest in Chinese herbal medicine and health tourism in Taiwan and Asia. Recent major changes include its name change in 2014 reflecting its strategic reorientation, and expanding regional partnerships to grow its product footprint in the disinfection and hygiene product markets across China and Asia.